Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025)

Inhibikase Therapeutics (IKT) has reported Short term Debt for 4 consecutive years, with $37944.0 the latest figure, recorded in Q2 2025.

• In Q2 2025, Short term Debt fell 75.07% year-over-year to $37944.0; the TTM figure through Jun 2025 stood at $37944.0 (down 75.07% YoY), while the FY2024 annual figure was $110517.0, down 26.37% from the prior year.
• Short term Debt retreated to $37944.0 in Q2 2025 per IKT's latest filing, from $74772.0 in the prior quarter.
• Across five years, Short term Debt topped out at $152224.0 in Q2 2024 and bottomed at $37944.0 in Q2 2025.
• Historically, Short term Debt has averaged $129475.2 across 4 years, with a median of $146368.5 in 2022.
• Annual changes were most pronounced in 2023 — Short term Debt climbed 4.92% — and 2025, when it tumbled 75.07%.
• Inhibikase Therapeutics' Short term Debt stood at $145836.0 in 2022, then grew by 2.92% to $150095.0 in 2023, then retreated by 26.37% to $110517.0 in 2024, then plunged by 65.67% to $37944.0 in 2025.
• Business Quant data shows IKT's Short term Debt at $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.